Optimizing CMC Strategy For Successful Scale-Up

In this segment from the Bioprocess Online Live event “Evolving CMC Strategies To Enable Next-Gen ADCs,” panelists Michael Torres, Ph.D. (CrossBridge Bio), Morris Rosenberg, Ph.D. (CrossBridge Bio), and Borys Shor, Ph.D. (OS Therapies and Manhattan BioSolutions) share advice on developing CMC strategies in a way that strengthens manufacturability through careful assay development and collaboration with CDMOs.